Erin Harris

Erin Harris

Click here to email Erin.
Erin Harris is chief editor of Cell & Gene and a contributing editor to Life Science Leader magazine. She studied English and psychology at Lafayette College and has 20+ years of experience in B2B publishing. Erin spent 10 years covering and reporting on the adoption of information technology from a B2B perspective. She’s written on technology topics ranging from Big Data and analytics to security and e-commerce. In each case, her reporting centered on innovations that improved operational efficiencies, fostered interdepartmental collaboration, or enhanced supply chains. Currently, she writes actionable information for professionals involved in the development and commercialization of cell and gene therapies. She covers the entire product lifecycle from basic research to commercialization. Erin has interviewed executives from Fortune 500 as well as startups. She has moderated panel discussions and has spoken at numerous industry events from large conferences to niche forums.

ARTICLES BY ERIN HARRIS

  • Inside Adaptimmune’s Road to ODD
    Inside Adaptimmune’s Road to ODD

    Adaptimmune’s SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform enables the engineering of T-cells to target and destroy cancer across multiple solid tumors. The FDA has granted Orphan Drug Designation (ODD) to SPEAR T-cells targeting MAGE-A4 (Adaptimmune’s ADP-A2M4 program) for the treatment of soft tissue sarcomas. Orphan Designation by FDA was created to encourage the development of drugs for rare diseases, such as sarcomas. I caught up with Dr. Elliot Norry, interim Chief Medical Officer at Adaptimmune, to learn more about the designation’s impact on the treatment of soft tissue sarcomas.

  • The Three Pillars Of Patient Advocacy In Industry
    The Three Pillars Of Patient Advocacy In Industry

    Patient advocacy plays a tremendously crucial role in the cell and gene sector. Jamie Ring, Head of Patient Advocacy at Spark Therapeutics and Cell & Gene Editorial Advisory Board member shared with me valuable information about role of patient advocacy in industry (i.e. what it is; what it’s not; the difference between patient advocacy in healthcare overall versus patient advocacy in gene therapy), which we will cover in detail in the coming weeks. To start, Ring lists and explains the three pillars of the role of patient advocacy in industry.   

  • Progress On First Gene Therapy For DCM
    Progress On First Gene Therapy For DCM

    Dilated cardiomyopathy (DCM) is a condition that affects more than 3 million patients in the U.S. Recently subpopulations have been identified that develop DCM due to mutations in specific genes that have been shown to result in the development of DCM. One of these specific genes is the Bcl2-associated athanogene 3 (BAG3) gene.

  • AskBio Talks AAV Gene Therapy Success
    AskBio Talks AAV Gene Therapy Success

    I reached out to Dr. Jude Samulski, co-founder and chief scientific officer of AskBio, to learn more AskBio's recent acquisition of Synpromics and to better understand just how the end-to-end AAV gene therapy platform will affect and improve gene therapy in the United States.

  • Precision BioSciences Tackles Off-The-Shelf Cell Therapies
    Precision BioSciences Tackles Off-The-Shelf Cell Therapies

    Allogeneic cell therapy products are displaying encouraging clinical and pre-clinical results. Precision BioSciences — a genome editing company known for its proprietary ARCUS genome editing platform, recently announced the opening of its Manufacturing Center for Advanced Therapeutics (MCAT), the first in-house current Good Manufacturing Process (cGMP) compliant manufacturing facility in the United States dedicated to genome-edited, off-the-shelf CAR-T cell therapy products. I caught up with Matt Kane, Chief Executive Officer and co-founder of Precision BioSciences to learn more about the manufacturing center and what that means for commercial launch.

  • Part 2: Adaptimmune’s Deep Dive into Manufacturing & Process Development
    Part 2: Adaptimmune’s Deep Dive into Manufacturing & Process Development

    In Part 1 of our two-part series with Adaptimmune, CEO James Noble, who has announced his retirement since the publication of this article, provided thoughtful insight on the status of combatting solid tumors as well as the ongoing pricing issue affecting the cell and gene therapy sector. Here in Part 2, along with John Lunger, SVP, Manufacturing and Supply Chain, and Mark Dudley, SVP, Product Development at Adaptimmune, we dig deeper into the topics discussed in Part 1 — we shed granular light on how pricing will affect manufacturing; we talk outsourced versus in-house manufacturing and more. 

  • Orchard Therapeutics Tackles ADA-SCID, MLD, And Much More
    Orchard Therapeutics Tackles ADA-SCID, MLD, And Much More

    On the heels of our sister print publication, Life Science Leader’s cover story on the whirlwind rise of Orchard Therapeutics, I had the opportunity to talk to company’s Co-Founder and Chief Scientific Officer, Dr. Bobby Gaspar about how the company has developed innovative gene therapies to treat CNS diseases, such as metachromatic leukodystrophy (MLD), tackle ADA-SCID, and more.

  • Expected Outcomes Of Minovia Tx’s MAT Clinical Trial
    Expected Outcomes Of Minovia Tx’s MAT Clinical Trial

    Minovia Therapeutics recently announced dosing of the first patient in a Phase I/II clinical trial of the company’s Mitochondrial Augmentation Therapy (MAT) for the treatment of Pearson syndrome. As stem cell transplantations and cellular therapies continue to gain momentum rapidly, this is an example of trial that could pave the way for the development of treatments for all mitochondrial diseases.

  • Breaking Down Pricing Of Cell & Gene Therapies
    Breaking Down Pricing Of Cell & Gene Therapies

    Erin Harris, Editor-In-Chief, Cell & Gene conferred with several SMEs in the cell and gene sector to get their take on the challenges for both industry and patient associated with cell and gene therapy prices, and what can be done, realistically, to bring costs down over time.

  • Adaptimmune’s CEO On Pricing And Next-Gen Immuno-Oncology
    Adaptimmune’s CEO On Pricing And Next-Gen Immuno-Oncology

    James Noble, CEO of Adaptimmune, explains where the industry is with attacking solid tumors and sheds light on the ever-present pricing issue.